

# PREDICT > TO PREVENT



## Profile

- > Identifies patients at risk for early-stage colorectal cancer
- > Simple test that does not require stool or blood sample
- > Can improve compliance rates as physician, rather than the patient, collects sample – unlike FOBT
- > Low-cost “gatekeeper” test could enable more efficient use of colonoscopy in screening for colorectal cancer

TSX: PMD  
Amex: PME  
www.premdinc.com

Investor/Media Contact:  
Sarah Borg-Olivier  
Director, Communications  
T: 416-222-3449 ext. 27  
sbolivier@premdinc.com

Business Development Contact:  
Tim Currie  
VP, Corporate Development  
T: (416) 222-3449 ext. 23  
tcurrie@premdinc.com



## ColorectAlert™

### Colorectal Cancer

- > Third most deadly cancer in North America – 63,670 deaths expected in 2006
- > Curable more than 90% of the time, if caught in the early stages
- > Only 39% of colorectal cancers are discovered at an early localized stage
- > Cancer experts recommend regular screening over age 50

### How it Works

- > Identifies a cancer-associated sugar in a sample of rectal mucus
- > Physician collects sample by digital rectal exam
- > Sample treated with reagents and changes color
- > Color change measured with spectrophotometer to generate test result

### Early-Stage Disease

- > Higher sensitivity for early-stage colorectal cancer than other low-cost screening tests
- > ColorectAlert is the only low-cost test reporting sensitivity greater than 50% for early-stage cancer

### Improving Compliance

- > Unlike other screening tests, with ColorectAlert, the physician, not the patient, collects the sample
- > No dietary restrictions or patient preparation required
- > No messy procedures

### Economically Practical

- > Low-cost “gatekeeper” test that enables more efficient use of costly procedures like colonoscopy and genetic testing
- > Health economic study showed significant savings in screening model using ColorectAlert as front-line test vs. fecal occult blood tests (FOBT)

### Patent and Regulatory Status

- > ColorectAlert has not been submitted for regulatory approval in any jurisdiction
- > 22 patents issued and pending in key markets on the mucus sample technology and nine related to color measurement process

